サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1345434

サイトカインの世界市場-2023年～2030年

Global Cytokine Market - 2023-2030

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
サイトカインの世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

世界のサイトカイン市場は、2022年に723億米ドルに達し、2023-2030年の予測期間中にCAGR 7.6%で成長し、2030年には1,322億米ドルに達すると予測されています。

サイトカインと呼ばれる小さなタンパク質は、血液細胞や免疫系細胞の発達や活性を制御する上で重要な役割を果たしています。サイトカインが放出されると、免疫系が機能するようシグナルを送ります。身体の免疫学的および炎症反応をサポートするすべての血液細胞およびその他の細胞は、サイトカインの影響を受けます。異常細胞を死滅させ、正常細胞を長生きさせるシグナルを伝達することで、抗がん作用もサポートします。

サイトカインを標的とする治療法は、過度に注目されています。関節リウマチなどの自己免疫疾患や炎症性腸疾患など、さまざまな疾患を治療するために、研究者や製薬会社によってサイトカイン活性を改変する薬剤が開発されています。組織の再生と修復にはサイトカインが不可欠です。創傷治癒や筋肉再生のような多くの状況において、研究者たちはサイトカインがどのように治癒や組織再生を助けるために使用されるかを研究しています。

ダイナミクス

新技術の進歩

がん免疫療法は、がん治療に有効であることが示されているサイトカインに大きな影響を受け続けるかもしれません。クローン化されたサイトカインは、さまざまながん、C型肝炎、B型肝炎の治療に利用されています。さらに、サイトカインは、炎症、感染、免疫に反応して生成されるとき、がんの成長を防ぐのを助けることができます。市場シェアが最も高いのは、がんの治療におけるサイトカインの使用によるものと予想されます。

例えば、National Cancer Institute 2022に掲載された記事によると、マウスを使った最近の研究で、科学者たちはがんを治療するために腹部の腫瘍の近くに置くことができる小さな「薬工場」を作り出したことが明らかになっています。卵巣がんと大腸がんのげっ歯類モデルにおいて、薬物工場は免疫刺激サイトカインであるインターロイキン2（IL-2）を産生することによって腫瘍を根絶しました。

2022年から、卵巣がん患者を対象としたこの戦略の臨床試験が開始される予定です。サイトカインの一例としてIL-2があります。IL-2は「免疫系の戦闘細胞であるT細胞の強力な活性化因子として知られており、がん細胞を根絶するT細胞の正常な能力を高める」。したがって、技術革新の台頭は市場の拡大を加速させる助けとなります。

臨床試験の増加

サイトカイン関連の臨床試験や投資の増加には多くの要因があり、これらは科学的発展と医薬の大きな進歩の可能性を示しています。バイオテクノロジーと製薬研究の発展により、サイトカインをベースとしたより集中的で効率的な治療法の開発が可能になっています。組換えDNA技術の使用により、サイトカインはより選択的に、より少ない悪影響で生産することができます。投資家や製薬会社は、新薬を開発し、医療を大幅に改善することに関心を持っています。革新的なサイトカインベースの医薬品が開発されれば、研究や臨床試験への資金提供は拡大する可能性があります。

例えば、2023年5月、米国食品医薬品局（FDA）は、サイトカイン放出症候群（CRS）の安全で効果的な治療法を研究している臨床段階のバイオテクノロジー企業であるCytoAgents, Inc.に対して、研究を進める許可を承認しました。この承認により、治験薬（IND）申請中のCAR T細胞療法を受けているリンパ腫患者のCRSを治療する薬剤CTO1681の米国フェーズ1b/2a臨床試験の開始が許可されました。悪性腫瘍に対してCAR T細胞療法を受けている患者の大多数がCRSおよび関連する神経毒性を有することから、この分野には大きなアンメット・メディカル・ニーズが存在します。

さらに、2023年1月、新規および既存の投資家を利用して、サイトカイン療法を提供するSynthekine Inc.は、The Column Groupが率いる1億米ドルのシリーズC資金調達の成功を発表しました。同社のIL-12パーシャルアゴニストプログラムは、現在IND取得可能試験中であり、今回の資金調達によりさらに前進することになります。IL-12はがんを治療する可能性を秘めた強力なサイトカインですが、その投与は治療域の制限や患者の生命を脅かす副作用の可能性によって制約されてきました。このように、上記の要因は市場の成長を加速させるのに役立ちます。

サイトカインは体内での半減期が短い

サイトカインは、その生理的機能、調節機能、免疫反応をダイナミックに制御する免疫システムの必要性から、体内での半減期が短いです。例えば、サイトカインと呼ばれるシグナル伝達分子は免疫反応を調整します。これらの反応を迅速かつ正確に制御することが免疫系には必要です。サイトカインは半減期が短いため、生成、放出、分解が速く、免疫系は状況の変化に応じて反応を調整することができます。

これらの生物学的製剤の限られた有効性は、その短い半減期によってかなり妨げられています。これらのタンパク質の安定性が向上すれば、これらの薬剤の投与頻度や投与量を減らすことができるかもしれません。その結果、研究者たちは、生体内でのサイトカインの半減期を長くし、特定の組織や臓器に特異的に標的化する技術を数多く生み出しました。このように、体内での半減期が短い薬物は、市場拡大の妨げとなります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 新技術の進歩
      • 臨床試験の増加
    • 抑制要因
      • サイトカインは体内での半減期が短い
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 タイプ別

  • ケモカイン
  • インターフェロン
  • インターロイキン
  • 腫瘍壊死因子（TNF）
  • モノカイン
  • リンパカイン
  • コロニー刺激因子（CSF）

第8章 用途別

  • がん
  • 整形外科
  • 皮膚科学
  • その他

第9章 エンドユーザー別

  • 製薬・バイオテクノロジー企業
  • CRO（医薬品開発業務受託機関）
  • 研究機関
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • CytoAgents
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Cullinan Oncology, Inc
  • Genentech, Inc
  • AbbVie Inc
  • Sanofi
  • Novartis AG
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • GenScript

第13章 付録

目次
Product Code: PH6781

Overview

Global Cytokine Market reached US$ 72.3 billion in 2022 and is expected to reach US$ 132.2 billion by 2030, growing with a CAGR of 7.6 % during the forecast period 2023-2030.

Small proteins known cytokines provide a key role in regulating the development and activity of blood and immune system cells. They signal the immune system to function once they are released. All blood cells and other cells that support the body's immunological and inflammatory responses are affected by cytokines. By transmitting signals that can cause abnormal cells to die and normal cells to live longer, they also support anti-cancer activities.

Therapies that target cytokines have attracted an excessive amount of attention. Drugs that modify cytokine activity are being developed by researchers and pharmaceutical companies to treat a variety of diseases, including autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease. In order to regenerate and repair tissue, cytokines are essential. In many situations, such as wound healing and muscle regeneration, researchers are looking into how cytokines might be used to aid healing and tissue regeneration.

Dynamics

The Advancement of New Technologies

Cancer immunotherapy may continue to be greatly influenced by cytokines, which have shown to be effective in the treatment of cancer. Cloned cytokines have been utilised to treat a variety of cancers, hepatitis C, and hepatitis B. Additionally efficient at treating a rare hereditary condition, cytokines. Additionally, cytokines can aid in preventing the growth of cancer when they are generated in response to inflammation, infection, and immunity. The highest market share is expected to be attributed to the therapeutic use of cytokines in the treatment of cancer.

For instance, according to an article published in National Cancer Institute 2022, stated that, a recent study in mice reveals that scientists have created small "drug factories" that can be put close to abdominal tumours to treat cancer. In rodent models of ovarian and colorectal cancer, the drug factories eradicated tumours by producing the immune-stimulating cytokine interleukin-2 (IL-2).

Beginning in 2022, clinical trials of this strategy on ovarian cancer patients are expected. An instance of a cytokine is IL-2, which "is a known potent activator of T cells-the fighter cells of the immune system-and boosts their normal ability to eradicate cancer cells." Therefore, the rise of innovations aids in accelerating market expansion.

The Rise in Clinical Trails

There are a number of factors contributing to the increase in cytokine-related clinical trials and investments, which represent both scientific developments and the possibility of major medicinal advancements. The development of more focused and efficient cytokine-based therapeutics has been made possible by developments in biotechnology and pharmaceutical research. With the use of recombinant DNA technology, cytokines can be produced with more selectivity and fewer negative effects. Investors and pharmaceutical corporations are interested in developing novel medicines and making substantial medical improvements. Research and clinical trial funding may grow if innovative cytokine-based medications are developed.

For instance, in May 2023, The U.S. Food and Drug Administration (FDA) approved CytoAgents, Inc., a clinical-stage biotechnology company working on a safe, effective treatment for Cytokine Release Syndrome (CRS), permission to move on with the study. This approval permits the beginning of a U.S. Phase 1b/2a clinical trial for the drug CTO1681 to treat CRS in lymphoma patients receiving CAR T-Cell Therapy under its Investigational New Drug (IND) application. As the majority of patients receiving CAR T therapy for their malignancy have CRS and related neurotoxicity, there is a significant unmet medical need in this field.

Moreover, in January 2023, Using both new and existing investors, Synthekine Inc., a provider of tailored cytokine therapies, announced the successful conclusion of a $100 million Series C fundraising headed by The Column Group. The company's IL-12 partial agonist programme, which is now in IND-enabling studies, will also be advanced with the help of the funds. Although IL-12 is a potent cytokine with the potential to treat cancer, its administration has been constrained by a restricted therapeutic window and potential life-threatening side effects in patients. Thus above factors helps to accelerate the market growth.

Cytokines Have a Short Half-Life in the Body

Due to their physiological functions, regulation, and the immune system's requirement for dynamic control over immunological responses, cytokines have a short half-life in the body. For instance, signalling molecules called cytokines coordinate immune responses. Controlling these reactions quickly and precisely is necessary for the immune system. Cytokines' fast production, release, and degradation due to their short half-lives enable the immune system to adjust its responses to changing circumstances.

These biologic medicines' limited effectiveness is considerably hampered by their brief half-lives. These drugs may be administered less frequently and at lower doses if the stability of these proteins were to increase. As a result, researchers have created a number of techniques to increase the half-life of cytokines in vivo and target them more specifically to particular tissues and organs. Thus, the market's expansion will be hindered by the drug's short half-life in the body.

Segment Analysis

The global cytokine market is segmented based on type, application, end users and region.

Cytokines Play a Critical Part in the Treatment of Cancer

With their capacity to regulate the immune response and have an impact on the tumour microenvironment, cytokines play a critical part in the treatment of cancer. It has been investigated to use cytokine-based therapeutics to take advantage of the immune system's capacity to identify and target cancer cells. The presentation of tumour antigens to immune cells can be aided by cytokines. As a result, the immune system is better able to identify cancer cells as foreign and respond to them effectively.

The tumour microenvironment, which consists of elements like blood vessels, stromal cells, and immune cells, can be influenced by cytokines. Cytokines can modify the tumour microenvironment to produce circumstances that are less conducive to tumour development and survival. Factors such as the increased prevalence of cancer, clinical research, and funding in the field of cancer therapy fuel segment growth.

For instance, according to National Cancer Institute, stated that, in the US, 2.0 million people will be given a cancer diagnosis in 2023. Breast cancer will be the most prevalent cancer diagnosis in 2018, affecting an estimated 297,790 women and 2,800 males. With 288,300 predicted cases, prostate cancer is the most prevalent cancer diagnosis among males and the second most frequent overall. The cancer segment is therefore expected to drive the segment growth over the projected period as a result of the causes mentioned above.

Geographical Penetration

Rising Product Approvals and Product Launches in the North American Region

North America is expected to dominate the cytokine market, due to the rising prevalence of cancer, product launches, FDA approvals of products, and research and development initiatives in the region.

For instance, on June 6, 2022, Amgen announced that the U.S. Food and Drug Administration (FDA) approved RIABNI (rituximab-arrx), a biosimilar to Rituxan, in combination with methotrexate for adults with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

Moreover, in January 2023, in order to include Canadian sites in the pivotal Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) randomised, controlled trial, CytoSorbents Corporation, a pioneer in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, has received regulatory approval from Health Canada. Therefore, as a result of all of the above, it is expected that North America would account for the largest market share throughout the projection period.

COVID-19 Impact Analysis

Cytokines are small proteins that play a crucial role in the immune response to infections, including COVID-19. An excessive release of cytokines, known as a cytokine storm, can have negative consequences. In COVID-19 patients, an increase in cytokine production is associated with severe symptoms, including acute lung injuries, blood clots, and fever. The severity of COVID-19 disease is linked to the virus-induced cytopathic effects and escape, which lead to the release of pro-inflammatory cytokines.

Mortality in COVID-19 patients has been linked to the presence of the so-called cytokine storm induced by the virus. Therefore, controlling cytokine storm is vital in COVID-19. Recent studies have shown that the level of inflammatory cytokines is increased in COVID-19, and several cytokines play a crucial role in the pathogenesis of COVID-19. Understanding the differences in cytokine expression is considered critical for the conquest of COVID-19.

By Type

  • Chemokines
  • Interferons
  • Interleukins
  • Tumor necrosis factor (TNF)
  • Monokines
  • Lymphokines
  • Colony-stimulating factors (CSF)

By Application

  • Cancer
  • Orthopedic
  • Dermatology
  • Others

By End Users

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On March 27, 2023, The U.S. Food and Drug Administration (FDA) has approved CLN-617, a fusion protein composed of two potent and synergistic antitumor cytokines, IL-2 and IL-12, with a collagen binding domain intended for retention in the tumour microenvironment (TME) after intratumoral injection, according to Cullinan Oncology, Inc., a biopharmaceutical company focused on modality-agnostic targeted oncology therapies. In a Phase 1 trial, Cullinan Oncology will initially assess CLN-617 in patients with advanced solid tumours.
  • On June 15, 2023, Genentech, a member of the Roche Group, announced that the FDA had approved Columvi (glofitamab-gxbm) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) that is not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma, following two or more lines of systemic therapy.
  • On May 19, 2023, The FDA has approved EPKINLYTM (epcoritamab-bysp), the first and only T-cell engaging bispecific antibody, for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL resulting from indolent lymphoma, and high-grade B-cell lymphoma (HGBL), following two or more lines of systemic therapies.
  • In May 2021, Ankyra Therapeutics and Lonza have signed an agreement to create a fusion protein for cytokines. In order to advance their first complex chemical targeting intratumoral injection in solid tumours into clinical development, Ankyra will draw on Lonza's experience with next-generation modalities. In order to meet a crucial deadline for an IND submission, Lonza will deliver a programme intended to shorten time to clinic.

Competitive Landscape

The major global players in the market include: CytoAgents, Cullinan Oncology, Inc, Genentech, Inc, AbbVie Inc, Sanofi, Novartis AG, Pfizer Inc, F. Hoffmann-La Roche Ltd , Merck KGaA, GenScript and among others.

Why Purchase the Report?

  • To visualize the global cytokine market segmentation based on type, application, end users and region,as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of cytokine market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global Cytokine market report would provide approximately 61tables, 58figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End Users
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The advancement of new technologies
      • 4.1.1.2. The rise in clinical trails
  • 4.2. Restraints
      • 4.2.1.1. Cytokines have a short half-life in the body
    • 4.2.2. Opportunity
    • 4.2.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Chemokines *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Interferons
  • 7.4. Interleukins
  • 7.5. Tumor necrosis factor (TNF)
  • 7.6. Monokines
  • 7.7. Lymphokines
  • 7.8. Colony-stimulating factors (CSF)

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cancer *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Orthopedic
  • 8.4. Dermatology
  • 8.5. Others

9. By End Users

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 9.1.2. Market Attractiveness Index, By End Users
  • 9.2. Pharmaceutical & Biotechnology Companies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Contract Research Organizations
  • 9.4. Research Institutes
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. CytoAgents *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Cullinan Oncology, Inc
  • 12.3. Genentech, Inc
  • 12.4. AbbVie Inc
  • 12.5. Sanofi
  • 12.6. Novartis AG
  • 12.7. Pfizer Inc
  • 12.8. F. Hoffmann-La Roche Ltd
  • 12.9. Merck KGaA
  • 12.10. GenScript

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us